<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105828</url>
  </required_header>
  <id_info>
    <org_study_id>Share wave fibro scan in HCC</org_study_id>
    <nct_id>NCT05105828</nct_id>
  </id_info>
  <brief_title>Predictive Power of Share Wave Fibro Scan in HCC After HCV Infection</brief_title>
  <official_title>Predictive Power of Share Wave Fibro Scan in HCC After HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shear wave electrography score allows stratification of HCC risk in a noninvasive and&#xD;
      reliable way and can guide the surveillance strategy for HCC in patients with CLD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver fibrosis is common to all chronic liver disease (CLD) , With time, this progressive&#xD;
      disruption of hepatic architecture can develop into cirrhosis, characterized by &quot;diffuse&#xD;
      conversion of normal liver architecture into structurally abnormal nodules&quot;, About1% to 4% of&#xD;
      patients with HCV-induced liver cirrhosis are diagnosed with HCC each year .&#xD;
&#xD;
      The historical gold standard for quantifying fibrosis is liver biopsy, but its invasive&#xD;
      nature and potential for complications make it unpopular among patients and impractical for&#xD;
      serial assessments of CLD. Furthermore, since histological lesions are not uniformly&#xD;
      distributed across the liver parenchyma, this allows for large sampling error. The need for&#xD;
      credible alternatives to biopsy has stimulated research into non-invasive methods of fibrosis&#xD;
      assessment, including serum biomarkers , axial imaging and transient elastography.&#xD;
&#xD;
      FibroScanâ„¢ (Echosens, Paris, France) allows a non-invasive liver stiffness measurement (LSM),&#xD;
      it is a relatively simple, highly reproducible and operator independent technique which&#xD;
      examines an area 100 times that of a biopsy, reducing sampling bias , Shear wave elastography&#xD;
      (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and&#xD;
      uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging&#xD;
      using the Aixplorer system provides a high frame-rate and may be able to provide more&#xD;
      accurate scoring of fibrosis .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Shear wave elastography score</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>it measures liver stiffness as it is a rapid technique taking less than 5 min that can be easily performed at bedside or in outpatient clinic,according to the manufacturer's recommendations and the machine scale result ranges from 2.5 to 75 kPa with normal value around 5.5 kPa</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>post Hepatitis C patients with hepatocellular carcinoma</arm_group_label>
    <description>post Hepatitis C patients with hepatocellular carcinoma above 18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>post Hepatitis C patients without hepatocellular carcinoma above 18 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Share wave fibro scan</intervention_name>
    <description>Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>post Hepatitis C patients with hepatocellular carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Post hepatitis C with HCC above 18 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post hepatitis C with HCC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hepatic encephalopathy, ascites or pregnancy, hepatorenal syndrome or hepato-pulmonary&#xD;
             syndrome, right side heart failure (liver congestion), extra hepatic tumors, history&#xD;
             of liver transplantation, cholestasis, and hepatitis B patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014 May 17;383(9930):1749-61. doi: 10.1016/S0140-6736(14)60121-5. Epub 2014 Jan 28. Review.</citation>
    <PMID>24480518</PMID>
  </reference>
  <reference>
    <citation>Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014 Jan 14;20(2):475-85. doi: 10.3748/wjg.v20.i2.475. Review.</citation>
    <PMID>24574716</PMID>
  </reference>
  <reference>
    <citation>Taylor-Robinson SD. Applications of magnetic resonance spectroscopy to chronic liver disease. Clin Med (Lond). 2001 Jan-Feb;1(1):54-60. Review.</citation>
    <PMID>11358078</PMID>
  </reference>
  <reference>
    <citation>Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C; Liver Fibrosis Study Group. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology. 2012 Dec;56(6):2125-33. doi: 10.1002/hep.25936. Epub 2012 Aug 31.</citation>
    <PMID>22767302</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mariam Roshdy Elkhayat</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

